论文部分内容阅读
目的：探讨氨磺必利与奥氮平治疗急性期精神分裂症的临床疗效及安全性。方法选取开县精神卫生保健院2014年7月—2016年2月收治的急性期精神分裂症患者92例，按入院先后顺序随机分为对照组与试验组，各46例。对照组患者给予奥氮平治疗，试验组患者给予氨磺必利治疗，两组患者均持续治疗6周。比较两组患者的临床疗效，阳性症状、阴性症状、一般病理的阳性与阴性症状量表（ PANSS）评分及不良反应发生情况。结果两组患者治疗总有效率、阳性症状、阴性症状、一般病理的PANSS评分比较，差异无统计学意义（ P﹥0.05）。试验组患者不良反应发生率低于对照组（ P﹤0.05）。结论氨磺必利在改善急性期精神分钟患者临床疗效及症状方面与奥氮平相当，但其安全性较高。“,”Objective To observe and analyze the clinical effect of amisulpride and olanzapine in the treatment of a-cute schizophrenia and the safety. Methods A total of 92 cases of acute schizophrenia patients were selected from July 2014 to February 2016 in Mental Hospital of Kaixian,which were randomly divided into control group and experimental group,46 cases in each group. Control group was treated with olanzapine,experimental group was treated with amisulpride,both groups were treated for 6 weeks. The clinical effect,PANSS score of positive symptoms,negative symptoms and general pathology and the in-cidence of adverse reactions were compared between the two groups. Results No statistically significant differences of the total efficiency rate and the PANSS score of positive symptoms,negative symptoms and general pathology was found between the two groups(P﹥0. 05). Experimental group of adverse reaction rate was lower than that of control group(P﹤0. 05). Conclusion Amisulpride in the treatment of acute schizophrenia has a same clinical effect with olanzapine,but amisulpride has a higher safety than olanzapine.